LDS

Company Overview

Snapshot

Founded in January 2012 by Nissim Garti, Prof. and Sharon Garti-Levi, PhD, LDS operates with 1–10 employees. The company focuses on drug delivery systems and secured a medical cannabis marketing deal in December 2016.

Business overview

LDS (Lyotropic Delivery Systems) is a biotechnology company specializing in advanced drug delivery systems based on liquid nano-sized formulations. Its proprietary technology enhances the transport of poorly absorbed macromolecules across the gastrointestinal wall into the bloodstream without altering the therapeutic compounds. This is achieved through modified soft and fluid gel mesophases, which are thermodynamically stable and composed of water nano-channels. LDS's portfolio includes oral, ocular, and transdermal applications, creating new uses for both generic and innovative drugs using generally recognized as safe (GRAS) components. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drug Delivery.

Strategic signal

In December 2016, LDS secured a significant medical cannabis marketing deal. This indicates the company's strategic expansion into the rapidly growing medical cannabis market, leveraging its nano-sized liquid drug delivery technology to potentially improve the efficacy and delivery of cannabis-based therapeutics. This move signals LDS's ability to adapt its core technology to new, high-demand applications within the pharmaceutical industry, suggesting potential for commercial growth and market diversification.

Company Intelligence Q&A

When was LDS founded and by whom?

LDS was founded in January 2012 by Nissim Garti, Prof. and Sharon Garti-Levi, PhD.

What is LDS's core technology?

LDS's core technology involves nano-sized liquid delivery systems that form modified soft and fluid gel mesophases to enhance the transport of poorly absorbed macromolecules across biological barriers without modifying the therapeutic compounds.

What significant deal did LDS secure in December 2016?

In December 2016, LDS secured a medical cannabis marketing deal, expanding its application areas within the pharmaceutical industry.

What markets does LDS's technology address?

LDS's technology addresses various markets including oral, ocular, and transdermal drug delivery applications, aiming to create new uses for generic and innovative drugs.

What is the primary sector of LDS?

LDS operates primarily within the Health Tech & Life Sciences sector, with a focus on Pharma & Medical Biotechnology and Drug Delivery.